Urothelial carcinoma of the urinary bladder (incl. renal pelvis, ureter)
Adjuvant Therapy
The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone as an adjuvant treatment for participants with pathologic high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection. The primary study hypothesis is that V940 in combination with pembrolizumab results in a superior disease-free survival (DFS) as assessed by the investigator compared to pembrolizumab alone in participants with high-risk MIUC after radical resection.
Testing of an alternative therapy with V940 + pembrolizumab versus placebo + pembrolizumab (previous standard)
